Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jun 14, 2021; 27(22): 3109-3120
Published online Jun 14, 2021. doi: 10.3748/wjg.v27.i22.3109
Table 1 Baseline characteristics of patients
Characteristics
n = 47
Age (yr), mean (range) ± SD44.9 (16-78) ± 18.7
Male/female, n (%)38/9 (80.9/10.6)
Disease duration (yr), mean (range) ± SD3.2 (0.1-42) ± 7.0
Disease extent, n (%)
Extensive colitis42 (89.4)
Left sided colitis5 (10.6)
CAI (Rachmilewitz index) mean (range) ± SD11.0 (7-17) ± 2.7
MES
MES 29 (19.1)
MES 338 (80.9)
Medication at study, n (%)
Oral 5-ASA21 (44.7)
Suppository 5-ASA7 (14.9)
Systemic steroids28 (59.6)
Immunomodulators10 (21.3)
Biologics11 (23.4)
History of biologics, n (%)12 (25.5)
Time to high trough level (d), mean (range) ± SD8.1 (0-46) ± 7.5
Table 2 Comparison between the failure and remission groups before tacrolimus induction
Characteristics
Remission (n = 30)
Failure (n = 17)
P value
Age (yr), mean ± SD41.33 ± 16.851.1 ± 20.70.084
Male/female, n (%)23/7 (76.7 / 23.3)15/2 (88.2/11.8)0.455
Disease duration (yr), mean ± SD2.0 ± 2.85.46 ± 10.90.098
Disease extent, n (%)
Extensive colitis 27 (90.0)15 (88.2)1
Left sided colitis3 (10.0)2 (11.8)
CAI (Rachmilewitz index), mean ± SD10.7 ± 2.411.7 ± 2.90.221
MES
MES 26 (20.0)3 (17.6)1
MES 324 (80.0)14 (82.4)
Medication at study, n (%)
Oral 5-ASA16 (53.3)5 (29.4)0.138
Suppository 5-ASA5 (16.7)2 (11.8)1
Systemic steroids19 (63.3)9 (52.9)0.546
Immunomodulators6 (20.0)4 (23.5)1
Biologics6 (20.0)5 (29.4)0.493
History of biologics, n (%)6 (20.0)6 (35.3)0.306
Time to high trough level (d), mean ± SD7.9 ± 8.18.5 ± 6.40.773
Table 3 Comparison of biological data before and after tacrolimus induction
Biological data
Remission (n = 30)
Failure (n = 17)
P value
Serum Alb at week 0 (g/dL) 2.83 ± 0.682.81 ± 0.720.897
Serum Alb at week 1 (g/dL) 2.94 ± 0.612.85 ± 0.780.651
Serum Alb at week 2 (g/dL) 3.29 ± 0.572.81 ± 0.730.015
Serum CRP at week 0 (mg/dL) 5.58 ± 5.755.44 ± 5.45)0.933
Serum CRP at week 1 (mg/dL) 0.88 ± 2.291.12 ± 1.510.696
Serum CRP at week 2 (mg/dL) 0.54 ± 1.501.17 ± 1.630.191
Hb at week 0 (g/dL) 11.2 ± 1.9011.32 ± 2.060.871
Hb at week 1 (g/dL) 10.65 ± 1.6011.15 ± 1.770.326
Hb at week 2 (g/dL) 10.78 ± 1.7110.89 ± 1.880.837
WBC at week 0 (/μL) 8660.00 ± 4498.658846.47 ± 3876.210.887
WBC at week 1 (/μL) 5958.00 ± 2444.206618.24 ± 2201.220.362
WBC at week 2 (/μL) 5473.00 ± 2095.786672.35 ± 2154.370.069
Table 4 Comparison of biological data ratio after tacrolimus induction
Rate of biological data
Remission (n = 30)
Failure (n = 17)
P value
Week 1/week 0 Alb ratio1.05 ± 0.141.02 ± 0.130.429
Week 2/week 0 Alb ratio1.19 ± 0.201.02 ± 0.160.003
Week 1/week 0 CRP ratio0.28 ± 0.491.28 ± 3.800.159
Week 2/week 0 CRP ratio0.16 ± 0.231.42 ± 4.280.112
Week 1/week 0 Hb ratio0.96 ± 0.131.01 ± 0.180.315
Week 2/week 0 Hb ratio0.97 ± 0.130.98 ± 0.140.892
Week 1/week 0 WBC ratio0.77 ± 0.320.84 ± 0.330.520
Week 2/week 0 WBC ratio0.72 ± 0.300.86 ± 0.400.194
Table 5 Multivariate analysis for predicting failure during 3 mo after tacrolimus induction
VariableUnivariate analysis
Multivariate analysis
HR
95%CI
P value
HR
95%CI
P value
Week 2/week 0 Alb ratio ≤ 13.6321.396-9.4450.0087.1952.011-25.740.002
Age1.0260.998-1.0550.0721.0090.976-1.0420.599
Sex (male)2.1390.489-9.3620.3132.4200.435-13.450.313
Disease extent (extensive colitis)1.0620.243-4.6400.9374.6650.554-39.300.157
MES 31.1880.341-4.1370.7870.4620.142-1.5030.200
Medication
Oral 5-ASA0.4500.158-1.2770.1330.5780.191-1.7440.331
Suppository 5-ASA0.6520.149-2.8530.5700.2470.035-1.7440.161
Systemic steroids0.7290.281-1.8900.5150.6360.193-2.0940.457
Immunomodulators1.1520.375-3.5430.8051.5160.391-5.8850.548
Biologics1.4000.493-3.9780.5270.9240.173-4.9200.926